1. Home
  2. INSM vs GFI Comparison

INSM vs GFI Comparison

Compare INSM & GFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • GFI
  • Stock Information
  • Founded
  • INSM 1988
  • GFI 1887
  • Country
  • INSM United States
  • GFI South Africa
  • Employees
  • INSM N/A
  • GFI N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • GFI Precious Metals
  • Sector
  • INSM Health Care
  • GFI Basic Materials
  • Exchange
  • INSM Nasdaq
  • GFI Nasdaq
  • Market Cap
  • INSM 12.5B
  • GFI 13.0B
  • IPO Year
  • INSM 2000
  • GFI 2007
  • Fundamental
  • Price
  • INSM $72.90
  • GFI $14.95
  • Analyst Decision
  • INSM Strong Buy
  • GFI Hold
  • Analyst Count
  • INSM 16
  • GFI 4
  • Target Price
  • INSM $83.64
  • GFI $14.93
  • AVG Volume (30 Days)
  • INSM 1.6M
  • GFI 3.1M
  • Earning Date
  • INSM 10-31-2024
  • GFI 11-29-2024
  • Dividend Yield
  • INSM N/A
  • GFI 2.62%
  • EPS Growth
  • INSM N/A
  • GFI N/A
  • EPS
  • INSM N/A
  • GFI 0.70
  • Revenue
  • INSM $342,958,000.00
  • GFI $4,358,300,000.00
  • Revenue This Year
  • INSM $18.96
  • GFI $18.54
  • Revenue Next Year
  • INSM $41.96
  • GFI $26.28
  • P/E Ratio
  • INSM N/A
  • GFI $21.25
  • Revenue Growth
  • INSM 22.13
  • GFI 1.30
  • 52 Week Low
  • INSM $21.92
  • GFI $12.19
  • 52 Week High
  • INSM $80.53
  • GFI $18.97
  • Technical
  • Relative Strength Index (RSI)
  • INSM 51.18
  • GFI 46.47
  • Support Level
  • INSM $64.86
  • GFI $13.22
  • Resistance Level
  • INSM $73.95
  • GFI $15.07
  • Average True Range (ATR)
  • INSM 2.98
  • GFI 0.41
  • MACD
  • INSM 0.26
  • GFI -0.07
  • Stochastic Oscillator
  • INSM 72.73
  • GFI 54.34

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About GFI Gold Fields Limited

Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.

Share on Social Networks: